NCT02675413View on ClinicalTrials.gov

Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2016

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
Interventions
DRUG

Dimethyl Fumarate

Open-label

Trial Locations (2)

63110

Washington University (John L. Trotter MS Center), St Louis

98122

Swedish Neuroscience Institute, Seattle

Sponsors

Collaborators (1)

Biogen
All Listed Sponsors
collaborator

Biogen

INDUSTRY

lead

Washington University School of Medicine

OTHER